CLYYF - Celyad: Early Stage CAR-T Company With A Different Approach
Introduction
Celyad (CYAD) is a clinical-stage biopharmaceutical company, focusing on the development of CAR-T cell therapy for treating cancers. The company has both autologous and allogeneic technological platforms for CAR-T and has 2 international partnerships with Novartis and Horizon Discovery. In this article, I will cover Celyad’s clinical pipeline and progress and the company’s prospects for investments.
Clinical Pipeline
As briefly mentioned, the company is working on both autologous and allogeneic CAR-Ts, both platforms are NKG2DL-based and target both hematological malignancies and solid tumors. The full list of its clinical pipeline is listed